Cipla Limited (Cipla) announced that it has agreed to further invest INR 42 crore (approx.) in digital tech company GoApptiv Private Limited (GoApptiv). In line with Cipla’s ambition to strengthen investments in channels of the future, this development will further expand Cipla’s presence across the healthcare continuum, especially to the underserved population by enabling greater…
Cipla Limited referred to as Cipla announced that its wholly-owned UK subsidiary, Cipla (EU) Limited (Cipla EU) has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH (Ethris), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation. The investment will facilitate a long-term strategic partnership…
Cipla Limited (Cipla) announced that it has agreed to acquire additional stake for INR 25.90 cr. in digital tech company GoApptiv Private Limited (hereinafter referred as “Goapptiv”) and post completion of the deal, Cipla’s total stake in GoApptiv will increase to 22.02% on a fully diluted basis. The investment will be made in equity shares…
Cipla Limited, a global pharmaceutical company and Kemwell Biopharma Private Limited, a leading biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced execution of a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space,…
Cipla Limited announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla’s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits. Cipla is staying true to its promise…
Cipla Limited announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with…
Pharma major Cipla announced it has re-appointed Umang Vohra as Managing Director and Global Chief Executive Officer for a period of five years, effective from 1st April, 2021. “In compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of Nomination…
Cipla Limited announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel in India. The product is indicated for the treatment of ICE due to Buerger’s disease and atherosclerotic peripheral arterial disease. It is the first allogeneic cell therapy to…
Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients. This agreement is part of Cipla’s efforts to enhance…